Danielle Bond on Muck Rack

Danielle Bond

Australia, Melbourne
As seen in: Nature, Wiley Online Library, Springer, Modern Ghana, EIN News, Dialnet - Universidad de La Rioja, EIN Presswire, Future Medicine, IABC
Brand builder. The views expressed are my own
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Danielle

Contact Danielle, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Resiliência na cadeia de suprimentos: estudo de caso em uma indústria metalmecânica

|
By Paulo de Oliveira, Danielle Bond, Vanessa Brunnquel
| Dialnet - Universidad de La Rioja
Resiliência na cadeia de suprimentos: estudo de caso em uma indústria metalmecânica Autores: Vanessa Brunnquel, Paulo Vitor de Oliveira, Danielle Bond, Luciana Rosa Leite, Carla Roberta Pereira Localización: Suma de Negocios, ISSN-e 2027-5692, ISSN 2215-910X, Vol. 9, Nº. 19, 2018, págs.
Open in Who Shared Issue with article?

Hypomethylating agents induce epigenetic and transcriptional heterogeneity with implications for acute myeloid leukemia cell self-renewal - Leukemia

|
By Danielle Bond, Sean Burnard, Heather Murray, Matthew Dun, Nikola Bowden, Anoop K. Enjeti, Nicole M. Verrills, Carlos Riveros
| Nature
To The Editor: DNA hypomethylating agents (HMAs), such as azacytidine (AZA, 5-azacytidine) and decitabine (DAC, 2’-deoxy-5-azacytidine), are used to treat acute myeloid leukaemia (AML) and myelodysplastic neoplasm. However, low response rates and therapy-resistant relapse remain significant challenges [1]. Reasoning that HMA-resistant relapse could originate from rare cells that evade and adapt to treatment, we sought to characterise heterogeneous responses to HMA treatment in AML cells.
Open in Who Shared Issue with article?

Hypomethylating agents induce epigenetic and transcriptional heterogeneity with implications for AML cell self-renewal.

|
By Danielle Bond, Sean Burnard, Kumar Uddipto, Kooper V Hunt
| biorxiv.org
A.K.E. declares the following competing interests: advisory board and honoraria from AbbVie, Astellas, Gilead, Servier, Jazz, Otsuka/Astex, and RACE Oncology; speaker fees from AbbVie, Otsuka/Astex, Astellas and Jazz; Research Funding from RACE oncology and Otsuka/Astex. N.A.B. receives research funding from Merck KGaA and Bristol Myers Squibb.
Open in Who Shared Issue with article?
See all 22 articles

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Get in touch with Danielle

Contact Danielle, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack
 •  Privacy  •  Terms  •  Security and Legal  •   •   •   • 

© 2026 Muck Rack

SOC 2® Certified